Showing 2251-2260 of 3315 results for "".
- Oculis Provides Updates on Late-Stage Clinical Trials; Announces Leadership Appointmentshttps://modernod.com/news/oculis-provides-updates-on-late-stage-clinical-trials-announces-leadership-appointments/2482135/Oculis provided updates its late-stage clinical trials, and also announced senior appointments to its management and advisory teams. The announcements were made during it R&D Day on Wednesday, February 28. “2024 promises to be another exciting year for Ocu
- Opthea Names New Clinical and Regulatory Leadership Membershttps://modernod.com/news/opthea-names-new-clinical-and-regulatory-leadership-members/2482091/Opthea announced the appointment of Julie Clark, MD, MS, as Senior Vice President (SVP), Clinical Development; and Fang Li, PhD, RAC, as SVP, Regulatory Affairs, effective February 1, 2024. Dr. Clark and Dr. Li will report to Opthea Chief Executive Officer Frederic Guerard, PharmD,
- EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-data-from-the-phase-2-davio-2-trial-of-eyp-1901-in-wet-amd/2481990/In a phase 2 study, EyePoint Pharmaceuticals’ wet AMD drug candidate demonstrated noninferiority to Eylea—with a less frequent dosing regimen. EyePoint leadership said the sustained-release implant could represent a 'paradigm-altering maintenance treatment' for patients with w
- Study: Racial Disparities in Glaucoma Care Persist, Regardless of Socioeconomic Statushttps://modernod.com/news/study-racial-disparities-in-glaucoma-care-persist-regardless-of-socioeconomic-status/2481961/Many studies have shown that glaucoma is more common and more severe in Black and Hispanics than in Whites, but less is known about the impact of racial differences and socioeconomic status on vision loss and individual utilization of health care resources among glaucoma patients, according
- Opthea Announces Changes to Executive Leadershiphttps://modernod.com/news/opthea-appoints-us-based-leadership-with-fred-guerard-as-ceo-and-peter-lang-as-cfo/2481918/Opthea announced that the company’s Chief Executive Officer, Megan Baldwin, PhD, will transition to Founder and Chief Innovation Officer, effective today. The company says the move is reflective of the company’s strategy to advance its US and global presence and commercialization
- BioTissue Presents New Data for Cryopreserved Amniotic Membrane Therapyhttps://modernod.com/news/biotissue-presents-new-data-for-cryopreserved-amniotic-membrane-therapy/2481880/Findings of a new multicenter, retrospective study conducted on patients with moderate to severe dry eye disease (DED) treated with BioTissue’s self-retained Prokera Slim Amniotic Membrane corneal bandage show significantly improved patient outcomes in less time, according to
- Optometry and Vision Science Names New Editor-in-Chiefhttps://modernod.com/news/optometry-and-vision-science-announces-new-editor-in-chief/2481744/The American Academy of Optometry (AAO) announced that David Elliott, PhD, FCOptom, FAAO, is the new editor-in-chief of Optometry and Vision Science (OVS). Mr. Elliott succeeds Michael Twa, OD, PhD, FAAO, who is stepping down from the role after 7 years.
- Annexon Announces Topline Data from Phase 2 Trial of ANX007 in Geographic Atrophyhttps://modernod.com/news/annexon-announces-topline-data-from-phase-2-trial-of-anx007-in-geographic-atrophy/2481637/Annexon announced topline results from its ARCHER phase 2 trial of ANX007 in patients with geographic atrophy (GA). The primary endpoint of mean rate of change (slope) in GA lesion area compared to sham at 12 months did not reach statistical significance. A 6.2% reduction in lesion
- Aviceda Announces 3 Presentations on AVD-104, its Lead Glyco-mimetic Nanoparticle, As Treatment for GA at ARVOhttps://modernod.com/news/aviceda-announces-3-presentations-on-avd-104-its-lead-glyco-mimetic-nanoparticle-as-treatment-for-ga-at-arvo/2481507/Aviceda Therapeutics announced its upcoming oral and poster presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans, April 23-27, 2023. Detailed results from each of these three studies will be reported at the conference.
- Survey: Employees Value Vision Care as Much as Dental, but Many are Leaving Benefits on the Tablehttps://modernod.com/news/survey-employees-value-vision-care-as-much-as-dental-but-many-are-leaving-benefits-on-the-table/2481495/A new survey conducted by The Harris Poll for XP Health finds that employees value vision care as much as dental, but many are confused about how to take advantage of it—even when they have vision benefits. According to the